Shares of Cytokinetics Inc. (NASDAQ:CYTK) lost more than half their value Friday after the drug developer said an experimental treatment for Lou Gehrig’s disease failed to slow the fatal condition’s progression more than a placebo in a clinical trial. Cytokinetics is studying tirasemtiv as a treatment for Lou Gehrig’s disease, or amyotrophic lateral sclerosis. Its midstage clinical trial compared the effects of tirasemtiv to a placebo on a scale that measured patients’ symptoms. Cytokinetics, Inc. (NASDAQ:CYTK) shares after opening at $5.23 moved to $5.45 on last trade day and at the end of the day closed at $4.59. Company price to sales ratio in past twelve months was calculated as 5.42 and price to cash ratio as 2.13. Cytokinetics, Inc. (NASDAQ:CYTK) showed a negative weekly performance of -51.79%.
Specialty pharmaceutical company, Egalet Corp (NASDAQ:EGLT), has announced on 1 April positive results for Phase 1 study of its Egalet-001, an abuse deterrent oral morphine product that is being developed for the treatment of severe chronic pain. Egalet-001 uses Eaglet’s proprietary technology which is designed to prevent any physical and chemical manipulation. Egalet Corp (NASDAQ:EGLT) shares fell -11.10% in last trading session and ended the day on $11.37. EGLT return on equity ratio is recorded as 141.10% and its return on assets is -217.90%.
For the Company’s quarter ended March 31, 2014 (3Q FY2014), ImmunoGen Inc. (NASDAQ:IMGN) reported a net loss of $37.5 million, or $0.44 per basic and diluted share, compared to a net loss of $1.4 million, or $0.02 per basic and diluted share, for the same quarter last year (3Q FY2013). Included in the current period is a $12.8 million ($0.15/share) non-cash expense related to the collaboration recently established with CytomX. ImmunoGen, Inc. (NASDAQ:IMGN) shares moved down -10.15% in last trading session and was closed at $12.39, while trading in range of $12.28 – $13.40. ImmunoGen, Inc. (NASDAQ:IMGN) year to date (YTD) performance is -15.54%.
Idera Pharmaceuticals Inc. (NASDAQ:IDRA) is a $273 million biotech company. The company recently reported positive results from its experimental drug that could give hope to B-cell lymphoma patients. However, shares of the company jumped significantly in the previous session on no specific news item. Idera Pharmaceuticals Inc. (NASDAQ:IDRA) weekly performance is 7.58%. On last trading day company shares ended up $2.98. Idera Pharmaceuticals Inc. (NASDAQ:IDRA) distance from 50-day simple moving average (SMA50) is -37.55%. Analysts mean target price for the company is $7.00.